Mindful Self-Compassion for Anxiety Disorders and Depression
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Georgetown University
- Study ID
- NCT05671419
- Status
- Recruiting
Conditions
- Agoraphobia
- Anxiety Disorders
- Generalized Anxiety Disorder
- Major Depressive Disorder
- Panic Disorder
- Social Anxiety Disorder
- Social Phobia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Mindful Self-Compassion — BEHAVIORALThe course teaching mindfulness meditation skills relevant to cultivating self-compassion.
Study Details
The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder.
Key Dates
- Start date
- Jan 16, 2022
- Status verified
- Jun 2025
- Primary completion
- Oct 31, 2025
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Mindful Self-CompassionMindful Self-Compassion (MSC) is a weekly class given for 8 weeks. The individual classes last about 2 hours each. The class is provided in a group setting.
- No Intervention: Treatment as Usual (TAU)The TAU arm will not receive the additional treatment from the study. Subjects will receive psychiatric treatment from their usual providers.
Primary Outcome Measure
Hospital Anxiety and Depression Scale [ Time Frame: 8 weeks ]
Central Contacts
- Charisma, Study Coordinator202-687-7283
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 |
Find similar trials in Washington D.C., DC
By condition
By specialty
By research site
Related Studies
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIVPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama
- Mindful Self-compassion for Anxiety and Depression: Impact of Delivery MethodRecruiting · Georgetown University · Washington D.C., District of Columbia
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPHASE2 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Evaluation of Patients With Mood and Anxiety Disorders and Healthy VolunteersRecruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland